The 20 Best Non-Small Cell Lung Cancer (NSCLC) Doctors Near Me

I am a part of the thoracic oncology program. I work with patients who have cancers of the lung, which includes non-small cell lung cancer, small cell lung cancer, and mesothelioma. My focus is on clinical care, clinical trials, and developing new therapies for these diseases. When I first meet with a patient, I want them to understand what their diagnosis is, because there are actually multiple diagnoses of lung cancer and each are treated differently. Then I discuss with a patient whether they are a candidate for therapies such as molecular therapy or immunotherapy, and make sure they have a clear understanding of the treatment plan. There are some very promising new therapies for these diseases and we are fortunate to have those available to patients here at Duke. That’s one of the unique things we offer as an academic medical center. Dr. Stinchcombe is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery. Dr. Stinchcombe is board certified in American Board Of Internal Med, Medical Oncology. Dr. Stinchcombe is currently accepting new patients.

Dr. Mihaela C. Cristea is a UCI Health hematologist oncologist who specializes in the treatment of gynecologic cancers.She earned her medical degree from the University of Medicine and Pharmacy of Iasi, Romania. She completed a residency in internal medicine at Monmouth Medical Center in Long Branch, N.J. She then completed a fellowship in medical oncology at the University of Florida - Health Science Center, Jacksonville.Her research focuses on evaluating novel therapies to improve patient outcomes in gynecologic malignancies. She has contributed to over 50 peer-reviewed publications in prominent medical journals.Cristea, who also speaks Romanian, brings extensive experience to UCI Health Chao Family Comprehensive Cancer Center. Dr. Cristea is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 25 other conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Lung Cancer, Virilizing Ovarian Tumor, and Endoscopy.

Sumanta Pal is an Oncologist practicing medicine in Duarte, California. Dr. Pal is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Heather Wakelee is an Oncologist practicing medicine in San Jose, California. Dr. Wakelee is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 17 other conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Thymectomy, and Tissue Biopsy.

Marwan Fakih is an Oncologist practicing medicine in Duarte, California. Dr. Fakih is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Squamous Cell Carcinoma of the Anal Canal (SCAC), Anal Cancer, Liver Embolization, and Endoscopy.

Tanya Dorff is an Oncologist practicing medicine in Duarte, California. Dr. Dorff is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Prostate Cancer, Penile Cancer, Familial Prostate Cancer, Prostatectomy, and Orchiectomy.

Sarah Hoffe is a Radiation Oncologist practicing medicine in Tampa, Florida. Dr. Hoffe is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 23 other conditions, according to our data. Her clinical expertise encompasses Pancreatic Cancer, Anal Cancer, Esophageal Cancer, Lymphadenectomy, and Pancreaticoduodenectomy. Dr. Hoffe is currently accepting new patients.

Marianna Koczywas is an Oncologist practicing medicine in Duarte, California. Dr. Koczywas is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 26 other conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, EGFR Positive Lung Cancer, and Tissue Biopsy.

Martin Edelman is an Oncologist practicing medicine in Philadelphia, Pennsylvania. He has been practicing medicine for over 44 years. Dr. Edelman is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer. Dr. Edelman is board certified in American Board Of Internal Medicine - Medical Oncology and American Board Of Internal Medicine - Internal Medicine.

Vincent Chung is an Oncologist practicing medicine in Duarte, California. Dr. Chung is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Endoscopy, and Gastrostomy.

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer. Dr. Tolaney is board certified in Medical Oncology. Dr. Tolaney is currently accepting new patients.

Dr. Meyer will serve as the lead medical oncologist for adult sarcoma patients, and will focus on building the Adult Sarcoma and Connective Tissue Oncology Program. In collaboration with pediatric oncologist David Loeb, M.D., Ph.D., and orthopaedic surgeon Kristy Weber, M.D., Meyer will bring novel therapies to the clinic for sarcoma patients. Meyer received his bachelors and masters degrees in cell and molecular biology from Stanford University. From there, he joined the Medical Scientist Training Program at Baylor College of Medicine and earned his medical degree followed by a doctorate in immunology. Meyer completed his residency at the University of Maryland and served as chief resident in medicine from 2004-2005. Afterward, he joined our fellowship program in medical oncology and has been working in the laboratory of Jonathan Powell, M.D., Ph.D., on projects relating to the characterization of molecular regulatory pathways involved in T-cell activation and energy. As a third-year fellow, Meyer served as the chief fellow for our Training Programs in Hematology and Medical Oncology and he received a Young Investigator Award from the American Society of Clinical Oncology in 2010. Dr. Meyer is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 34 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Osteosarcoma, and Salpingo-Oophorectomy. Dr. Meyer is board certified in American Board Of Internal Medicine. Dr. Meyer is currently accepting new patients.

Dr. O'Shaughnessy is a Medical Oncologist that focuses on breast cancer prevention and treatment. She founded The School of Breast Oncology, a program providing a curriculum-based program focused exclusively on breast cancer clinical management. Dr. O'Shaughnessy attended medical school at Yale University School of Medicine in New Haven, CT. She then completed her Internal Medicine residency at Massachusetts General Hospital in Boston, MA and a Medical Oncology fellowship at National Cancer Institute in Bethesda, MD. She is co-chair of Breast Cancer Research, chair of Breast Cancer Prevention Research at Baylor Charles A. Sammons Cancer Center and a member of the Scientific Advisory Board for US Oncology Research Network. Dr. O'shaughnessy is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Inflammatory Breast Cancer, and Tissue Biopsy. Dr. O'shaughnessy is board certified in Medical Oncology- American Board Of Internal Medicine, Medical Oncology- American Board Of Internal Med/Medical Oncology, Internal Medicine- American Board Of Internal Med, and Internal Medicine- American Board Of Internal Medicine. Dr. O'shaughnessy is currently accepting new patients.

Kevin Kalinsky is an Oncologist practicing medicine in Atlanta, Georgia. Dr. Kalinsky is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER2 Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Inflammatory Breast Cancer. Dr. Kalinsky is currently accepting new patients.

David Mcdermott is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Mcdermott is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Melanoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy. Dr. Mcdermott is board certified in American Board Of Internal Medicine. Dr. Mcdermott is currently accepting new patients.

Dr. Daniel Laheru is a cancer specialist in Baltimore, caring for patients with pancreatic cancer, colorectal cancer and neuroendocrine cancers. Dr. Laheru serves as co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at Johns Hopkins Medicine. Dr. Laheru received his undergraduate degree in chemistry from The University of Utah. He earned his M.D. at Baylor College of Medicine. He completed his residency at The University of Utah Hospital and Clinics and performed a fellowship in medical oncology at The Johns Hopkins University School of Medicine and The Johns Hopkins Oncology Center. Dr. Laheru joined the Johns Hopkins faculty in 2001. Dr. Laheru's research interests include pancreatic cancer and chemotherapy resistance in pancreatic cancer. With Elizabeth Jaffee, M.D., he developed a vaccine that supercharges the immune system and causes immune cells, which tend to be tolerant of cancer, to seek out and kill pancreatic cancer cells throughout the body. He has given numerous invited talks on pancreatic cancer and other cancers both nationally and internationally. He has authored over 200 papers focused on pancreatic cancer. Dr. Laheru serves as associate editor of Annals of Pancreatic Cancer. He has been recognized by the American Society of Clinical Oncology with the Young Investigator Award, by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins as an Isaac and Catharine Hecht Scholar and has been elected to the Miller-Coulson Academy of Clinical Excellence. He is a member of the American College of Physicians, the American Society of Clinical Oncology and the American Association for Cancer Research. Dr. Laheru is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 27 other conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Neuroendocrine Tumor, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Laheru is board certified in American Board Of Internal Medicine. Dr. Laheru is currently accepting new patients.

Adam M. Brufsky, MD, PhD, FACP, is professor of medicine at the University of Pittsburgh School of Medicine and also serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine's Department of Medicine. Dr. Brufsky is the medical director of the Magee-Women's Cancer Program, part of the UPMC Hillman Cancer Center, and UPMC Hillman Cancer Center; associate director for clinical investigations at UPMC Hillman Cancer Center; and codirector of the Comprehensive Breast Cancer Center.Dr. Brufsky is board-certified in internal medicine and medical oncology. He earned a medical and doctor of philosophy degrees from the University of Connecticut School of Medicine in Farmington, Conn.; completed a residency at Brigham and Women's Hospital, Harvard Medical School, and a fellowship at Dana-Farber Cancer Institute.Dr. Brufsky is a member of professional organizations, such as American Medical Association, Massachusetts Medical Society, American College of Physicians, American Society of Clinical Oncology, American Association for Cancer Research, Allegheny County Medical Society, Pennsylvania Medical Society, and Pennsylvania Oncologic Society. An active researcher, Dr. Brufsky has numerous abstracts and research articles in leading journals, and is principal investigator on a number of research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army - Breast Cancer Research Program. Dr. Brufsky is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and Gastrostomy. Dr. Brufsky is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Brufsky is currently accepting new patients.

Bradley Carthon is a Hematologist and an Oncologist practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 21 years. Dr. Carthon is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Prostatectomy. Dr. Carthon is board certified in American Board Of Internal Medicine, 2011. Dr. Carthon is currently accepting new patients.

Dr. Nilofer S. Azad is Professor of Oncology at Johns Hopkins University School of Medicine and serves as the Associate Cancer Center Director for Clinical Research for the Johns Hopkins Sidney Kimmel Cancer Center. Dr. Azad earned her medical degree and completed a residency in internal medicine at Baylor College of Medicine in Houston, Texas. She then completed a fellowship in oncology and hematology at the National Institute of Health's National Cancer Institute in Bethesda, Maryland where she served as chief fellow. Dr. Azad’s research focused on early phase drug development and the intersection of moving exciting laboratory findings into patients for new treatment options Dr. Azad joined the faculty at the Kimmel Cancer Center in 2008. Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a concentration in colorectal cancer, cholangiocarcinoma and pancreaticobiliary tract cancer. Her research efforts are dedicated to developing new drug combinations for patients with advanced cancer. In particular, Dr. Azad’s laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs. She is an active clinical trialist, leading multiple clinical trials of molecularly targeted agents for advanced cancer patients. Dr. Azad has received numerous grants for her work from entities such as the NCI (National Cancer Center), American Cancer Society, American Society of Clinical Research, Breakthrough Cancer Foundation, the Lustgarten Foundation, The Gateway Foundation, and the National Comprehensive Cancer Network, among others. She served as Principal for Johns Hopkins on the AACR Stand Up 2 Cancer Colorectal Cancer Dream Team and is a member of the Stand Up 2 Cancer Epigenetics Dream Team, leading the GI cancer initiatives for the group. Dr. Azad is a national leader in GI cancer, including serving as a member of the national NCI Colon Cancer Task Force and as Co-Chair of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. She has a presidential appointment to the National Cancer Advisory Board. Dr. Azad is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Colorectal Cancer, Pancreatic Cancer, Hepato-Pancreato-Biliary Surgery, and Colonoscopy. Dr. Azad is board certified in American Board Of Internal Medicine. Dr. Azad is currently accepting new patients.

Omer Kucuk is an Oncologist practicing medicine in Atlanta, Georgia. Dr. Kucuk is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Urothelial Cancer, Nephrectomy, and Prostatectomy. Dr. Kucuk is board certified in American Board Of Internal Medicine, 1989. Dr. Kucuk is currently accepting new patients.